Lupin Ltd.
Laxmi Towers, "B" Wing, 5th Floor
Bandra Kurla Comple
Mumbai
400 051
Tel: 91-22-56402222
Fax: 91-22-56402299
Website: http://www.lupinworld.com/
Email: ho@lupinworld.com
91 articles about Lupin Ltd.
-
Following the FDA’s approval in March, India-based Lupin is launching its generic thiamine hydrochloride injection USP in the U.S. for treating vitamin B1 deficiency.
-
Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington's drug Austedo.
-
Lupin Announces Executive Leadership Change
2/23/2022
Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets.
-
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
-
ForDoz Pharma partners with Lupin on development of 2 complex injectable products
8/20/2020
ForDoz Pharma has entered into an agreement with Lupin, to market and distribute 2 complex injectable products in advanced development stage at ForDoz, in US and its territories. The products are in the Oncology and Anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals. These two licensed products are flagship technology assets among ForDoz complex injectable pr
-
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
6/4/2020
Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto ® , a biosimilar to Enbrel ® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic art
-
Miller Law LLC, Hilliard & Shadowen LLP, Motley Rice LLC, and Cohen Milstein Sellers & Toll PLLC Announce Notice of Class Action for In re Loestrin 24 Fe Antitrust Litigation
10/1/2019
If You Purchased Loestrin 24 Fe, Minastrin 24 Fe and/or Their Generic Equivalent(s) a Class Action Lawsuit May Affect Your Rights
-
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
9/4/2019
Boehringer Ingelheim and Lupin Limited announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound as a potential targeted therapy for patients with difficult-to-treat cancers.
-
Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
2/1/2019
Lupin is pleased to announce that NaMuscla® (mexiletine) has been launched in Germany and the United Kingdom (UK).
-
AbbVie closed out 2018 by striking a nearly $1 billion licensing deal for India-based Lupin Limited’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
-
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to Treat Hematological Cancers
12/24/2018
Lupin Limited and AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
-
Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar
6/28/2018
Through the partnership agreement, Mylan will commercialize Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
-
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
5/24/2018
Lupin Confirms Validity of OMIDRIA Patents
-
$20 Million Class Action Settlement has been Reached for Purchasers of Solodyn®
4/30/2018
A proposed $20 million settlement has been reached in a class action lawsuit involving the antibiotic drug Solodyn®.
-
In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the company chose to override the results.
-
The FDA issued warning letters to Lupin for two of its manufacturing facilities in Goa and Pithampur, Indore.
-
With 80 New Jobs Already, Lupin Aims to Create Even More Opportunities at New Jersey Site
5/10/2017
-
Lupin Rumored to be In Talks for Sanofi's Inhaler Brand
3/6/2017
-
Lupin Receives EIR From U.S. FDA For Goa, March 2016 Inspection
11/7/2016
-
Lupin And MonoSolRx LLC Announce Licensing Agreement For Multiple Pediatric-Focused Products
10/6/2016